Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs American Superconductor Corporation (AMSC) Price & Performance

AbCellera Biologics IncTrade
American Superconductor CorporationTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs American Superconductor Corporation — how do they compare? AbCellera Biologics Inc trades at $9.99 (market cap $2.99B), while American Superconductor Corporation trades at $32.58 (market cap $1.56B). The key difference: AbCellera Biologics Inc is the larger of the two by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, American Superconductor Corporation nearer its low. Which is the better fit depends on your goals.

ABCLAMSC
Market Cap
$2.99B$1.56B
Sector
HealthTechnology
52-Week High
$9.76$66.68
52-Week Low
$2.78$25.95
Enterprise Value
$2.58B$1.42B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.

The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.

American Superconductor Corporation

AMSC trades at $32.64, up 5.32% in 24 hours, with a bearish technical signal from moving averages. Recent Q1 2026 earnings missed estimates despite record revenue growth, while Q4 2025 and Q1 2026 beat expectations. The company shows strong profitability with a net income margin of 42.56% and ROE of 30.16%, but faces margin pressure and a high EV/EBITDA of 65.73. News highlights record orders and backlog growth amid concerns over valuation and business mix.

Outlook is mixed: bullish fundamentals from earnings beats and order momentum contrast with bearish technicals and valuation risks. Opportunities lie in Grid and Wind segment expansion, but investors face headwinds from margin compression and competitive pressures. Analyst consensus leans buy (53.33%), suggesting cautious optimism for growth execution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About American Superconductor Corporation

AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.

Read more on AMSC